05.01.21

Novartis: Phase 3 Beovu Data Show Potential for Fluid Resolution in More DME Patients With Fewer Injections Versus Aflibercept

Source: Novartis

04.29.21

Adverum Biotechnologies Reports a Adverse Reaction of Hypotony in the INFINITY Trial Evaluating ADVM-022 in Patients With DME

Source: Adverum Biotechnologies

04.29.21

Heidelberg Engineering and RetInSight to Offer AI-Based OCT Fluid Quantification Solution

Source: Heidelberg Engineering

04.22.21

Ocuphire’s APX3330 for Retinal Diseases to be Presented at ARVO 2021

Source: Ocuphire

03.01.21

Retinal Therapeutics Development Company Oxular Completes $37 Million (£27 million) Financing

Source: Oxular

02.23.21

Asclepix Therapeutics Partners With Notal Vision on Home OCT Remote Monitoring in DME and AMD Clinical Trials

Source: Asclepix Therapeutics

02.16.21

Kodiak Sciences Announces 1-Year Data from Ongoing Phase 1b Study of KSI-301 in Patients with Retinal Vascular Diseases

Source: Kodiak Sciences

02.12.21

Genentech: New Phase 3 Data Show Faricimab the First Investigational Injectable Eye Medicine to Extend Time Between Treatment to Up to 4 Months

Source: Genentech

01.07.21

Adverum Biotechnologies Announces New GMP Gene Therapy Manufacturing Facility

Source: Adverum Biotechnologies

01.05.21

AsclepiX Therapeutics Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for DME

Source: AsclepiX Therapeutics

View more stories